LA NEUROINFLAMACIÓN COMO FACTOR PRONÓSTICO EN EL TRAUMATISMO CRANEOENCEFÁLICO GRAVE
DOI:
https://doi.org/10.56238/arev8n6-009Palabras clave:
Traumatismo Craneoencefálico, Neuroinflamación, Lesión Secundaria, Biomarcadores, NeuroprotecciónResumen
Este estudio analiza la arquitectura fisiopatológica de la neuroinflamación en el traumatismo craneoencefálico (TCE) moderado a grave, dilucidando los mecanismos de la lesión secundaria y su correlación con biomarcadores pronósticos y resultados clínicos. Mediante una revisión narrativa de la literatura, se investigó la transición del paradigma reduccionista a la biología de sistemas en la neuroprotección contemporánea. La cascada secundaria se consolida como un proceso multisistémico en el que la piroptosis, la formación de trampas extracelulares de neutrófilos (NET) y la activación del sistema del complemento operan sinérgicamente para exacerbar el edema citotóxico y vasogénico. Los biomarcadores estructurales, como la proteína ácida fibrilar glial (GFAP) y el neurofilamento ligero (NfL), así como citocinas específicas, como la IL-6 y la IL-1β, emergen como posibles predictores de gravedad, aunque la heterogeneidad fenotípica y la ausencia de valores de corte universales limitan su aplicabilidad clínica inmediata. La evidencia sugiere que la persistencia de un estado inflamatorio crónico es un determinante clave de la mortalidad tardía y del deterioro cognitivo persistente observado en los supervivientes. El fracaso histórico de las terapias dirigidas a un solo objetivo refuerza la necesidad de intervenciones multimodales integradas. En este contexto, el manejo del traumatismo craneoencefálico grave requiere abandonar las estrategias de bloqueo inmunitario inespecífico en favor de la inmunomodulación selectiva. La medicina de precisión, basada en la estratificación biológica individual y la comprensión de las ventanas temporales de la inflamación, es una de las principales fronteras científicas para mitigar la morbilidad y la mortalidad y optimizar la recuperación funcional a largo plazo, ofreciendo un enfoque personalizado para una patología marcadamente heterogénea.
Descargas
Referencias
ALAM, A. et al. Cellular infiltration in traumatic brain injury. Journal of Neuroinflammation, 2020. Disponível em: https://link.springer.com/article/10.1186/s12974-020-02005-x. DOI: https://doi.org/10.1186/s12974-020-02005-x
BEHZADI, F. et al. A systematic review and meta-analysis of major blood protein biomarkers that predict unfavorable outcomes in severe traumatic brain injury. Clinical neurology and neurosurgery, v. 242, p. 108312, 2024. Disponível em: https://doi.org/10.1016/j.clineuro.2024.108312. DOI: https://doi.org/10.1016/j.clineuro.2024.108312
BOURAS, M. et al. Immune modulation after traumatic brain injury. Frontiers in Medicine, 2022. Disponível em: https://www.frontiersin.org/articles/10.3389/fmed.2022.995044/full. DOI: https://doi.org/10.3389/fmed.2022.995044
BURDA, J. E.; SOFRONIEW, M. V. Reactive gliosis and the multicellular response to CNS damage and disease. Neuron, v. 81, n. 2, p. 229–248, 2014. Disponível em: https://pubmed.ncbi.nlm.nih.gov/24462092/ DOI: https://doi.org/10.1016/j.neuron.2013.12.034
CALDERONE, A. et al. The Role of Neuroinflammation in Shaping Neuroplasticity and Recovery Outcomes Following Traumatic Brain Injury: A Systematic Review. International Journal of Molecular Sciences, v. 25, n. 21, p. 11708–11708, 2024. Disponível em: https://pubmed.ncbi.nlm.nih.gov/39519259/ DOI: https://doi.org/10.3390/ijms252111708
CIRYAM, P. et al. Interleukin-6 in traumatic brain injury: a Janus-faced mediator in damage and repair. Journal of Neurotrauma, 2023. Disponível em: https://pubmed.ncbi.nlm.nih.gov/37166354/. DOI: https://doi.org/10.1089/neu.2023.0135
DOBSON, G. P.; MORRIS, J. L.; LETSON, H. L. Traumatic brain injury: from symptoms to systems in the 21st century. Brain Research, [s. l.], v. 1845, 149271, 15 dez. 2024. DOI: 10.1016/j.brainres.2024.149271. Disponível em: https://www.sciencedirect.com/science/article/pii/S0006899324005250?via%3Dihub. DOI: https://doi.org/10.1016/j.brainres.2024.149271
DOĞANYİĞİT, Z. et al. Neuroinflammatory mediators in traumatic brain injury. ACS Chemical Neuroscience, 2022. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35732021/.
HAMMAD, A.; WESTACOTT, L.; ZABEN, M. The role of the complement system in traumatic brain injury: a review. Journal of Neuroinflammation, v. 15, n. 1, 2018. Disponível em: https://doi.org/10.1186/s12974-018-1066-z. DOI: https://doi.org/10.1186/s12974-018-1066-z
HOSSAIN, I. et al. Blood biomarkers for traumatic brain injury: a narrative review of current evidence. Brain and Spine, v. 4, 2024. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC10951700/. DOI: https://doi.org/10.1016/j.bas.2023.102735
KORLEY, F. K. et al. Prognostic value of day-of-injury plasma GFAP and UCH-L1 concentrations for predicting functional recovery after traumatic brain injury in patients from the US TRACK-TBI cohort: an observational cohort study. The Lancet Neurology, v. 21, n. 9, p. 803-813, 2022. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35963263/. DOI: https://doi.org/10.1016/S1474-4422(22)00256-3
LIPSKY, R. H. et al. Traumatic brain injury: molecular biomarkers, genetics, secondary consequences, and medical management. Frontiers in Neuroscience, v. 18, 2024. DOI: 10.3389/fnins.2024.1446076. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC11500614/. DOI: https://doi.org/10.3389/fnins.2024.1446076
LIU, X. et al. Extracellular vesicles in traumatic brain injury. Frontiers in Immunology, 2022. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36741357/.
LIU, X. et al. Neuroinflammation of traumatic brain injury: roles of extracellular vesicles. Frontiers in Immunology, 2023. Disponível em: https://www.frontiersin.org/articles/10.3389/fimmu.2022.1088827/full. DOI: https://doi.org/10.3389/fimmu.2022.1088827
MALIK, S. et al. Inflammatory cytokines associated with mild traumatic brain injury and clinical outcomes: a systematic review and meta-analysis. Frontiers in Neurology, v. 14, 2023. Disponível em: https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2023.1123407/full. DOI: https://doi.org/10.3389/fneur.2023.1123407
MORGANTI-KOSSMANN, M. C. et al. Inflammatory response in acute traumatic brain injury: a double-edged sword. Current Opinion in Critical Care, v. 25, n. 2, p. 105–112, 2019. Disponível em: https://pubmed.ncbi.nlm.nih.gov/12386508/
MAHMOUD et al. Dysregulated brain-gut axis in the setting of traumatic brain injury: review of mechanisms and anti-inflammatory pharmacotherapies. Journal of neuroinflammation, v. 21, n. 1, 2024. Disponível em: https://doi.org/10.1186/s12974-024-03118-3. DOI: https://doi.org/10.1186/s12974-024-03118-3
MUHAMMAD, S. A. et al. Stem cell secretome in traumatic brain injury. Molecular Neurobiology, 2022. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35230664/.
OYOVWI MEGA OBUKOHWO et al. Microglia-mediated neuroinflammation in traumatic brain injury: a review. Molecular Biology Reports, v. 51, n. 1, 2024. Disponível em: https://doi.org/10.1007/s11033-024-09995-4. DOI: https://doi.org/10.1007/s11033-024-09995-4
RYU, J. K.; MCCABE, J. T.; CORPS, K. N. Microglial activation following traumatic brain injury: a double-edged sword. Journal of Neuroinflammation, 2021. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC5487478/
SAVIOLA, D. et al. Severe traumatic brain injury and long-term survival: a meta-analysis on life expectancy and mortality trends. Neurological Sciences, v. 47, n. 5, 2026. Disponível em: https://doi.org/10.1007/s10072-025-08706-6. DOI: https://doi.org/10.1007/s10072-025-08706-6
SIMON, D. W. et al. The far-reaching scope of neuroinflammation after traumatic brain injury. Nature Reviews Neurology, v. 18, p. 572–592, 2017. Disponível em: https://pubmed.ncbi.nlm.nih.gov/28186177/. DOI: https://doi.org/10.1038/nrneurol.2017.116
THOME, J. G. et al. Contributions of interleukin-1 receptor signaling in traumatic brain injury. Frontiers in Behavioral Neuroscience, v. 13, p. 287, 2020. Disponível em: https://www.frontiersin.org/articles/10.3389/fnbeh.2019.00287/full. DOI: https://doi.org/10.3389/fnbeh.2019.00287
SHAHIM, P. et al. Neurofilament light as a biomarker in traumatic brain injury. Neurology, v. 95, n. 6, p. e610-e622, 2020a. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32641538/.
SHAHIM, P. et al. Time course and diagnostic utility of NfL, Tau, GFAP, and UCH-L1 in subacute and chronic TBI. Neurology, v. 95, n. 6, p. e623-e636, 2020b. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32641529/. DOI: https://doi.org/10.1212/WNL.0000000000009985
THELIN, E. P. et al. Serial sampling of serum protein biomarkers for monitoring human traumatic brain injury dynamics: a systematic review. Frontiers in Neurology, v. 8, 2017. Disponível em: https://pubmed.ncbi.nlm.nih.gov/28717351/. DOI: https://doi.org/10.3389/fneur.2017.00300
TSITSIPANIS, D. et al. Inflammation biomarkers IL-6 and IL-10 may improve outcome prediction in traumatic brain injury. Journal of Neuroinflammation, 2023. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC10318605/.
WILSON, L. et al. A Manual for the Glasgow Outcome Scale-Extended Interview. Journal of Neurotrauma, v. 38, n. 17, p. 2435–2446, 2021. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC8390784/. DOI: https://doi.org/10.1089/neu.2020.7527
VAN DER VEEN et al. Pharmacotherapy to Improve Cognitive Functioning After Acquired Brain Injury: A Meta‐Analysis and Meta‐Regression. Clinical Pharmacology & Therapeutics, v. 115, n. 5, p. 971–987, 2024. Disponível em: https://doi.org/10.1002/cpt.3186. DOI: https://doi.org/10.1002/cpt.3186
VAN ERP, I. A. M. et al. Tackling Neuroinflammation After Traumatic Brain Injury: Complement Inhibition as a Therapy for Secondary Injury. Neurotherapeutics, [s. l.], v. 20, n. 1, p. 284-303, jan. 2023. DOI: 10.1007/s13311-022-01306-8. Disponível em: https://www.neurotherapeuticsjournal.org/article/S1878-7479(23)00122-8/fulltext. DOI: https://doi.org/10.1007/s13311-022-01306-8
WANG, J. et al. Neutrophil extracellular traps induce endothelial damage and exacerbate vasospasm in traumatic brain injury. Theranostics, [s. l.], v. 15, n. 17, p. 9221-9239, 16 ago. 2025. DOI: 10.7150/thno.115746. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC12439479/. DOI: https://doi.org/10.7150/thno.115746
WILDE, E. A. et al. A framework to advance biomarker development in the diagnosis, outcome prediction, and treatment of traumatic brain injury. Journal of Neurotrauma, v. 39, n. 7-8, p. 436-457, 2022. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35057637/. DOI: https://doi.org/10.1089/neu.2021.0099
ZHANG, X. et al. Targeting pyroptosis with nanoparticles to alleviate neuroinflammatory for preventing secondary damage following traumatic brain injury. Science Advances, [s. l.], v. 10, n. 2, eadj4260, 12 jan. 2024. DOI: 10.1126/sciadv.adj4260. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC10780956/. DOI: https://doi.org/10.1126/sciadv.adj4260
ZHENG, R.; LEE, K.; QI, Z.; WANG, Z.; XU, Z.; WU, X.; MAO, Y. Neuroinflammation following traumatic brain injury: take it seriously or not. Frontiers in Immunology, v. 13, 2022. Disponível em: https://www.frontiersin.org/articles/10.3389/fimmu.2022.855701/full. DOI: https://doi.org/10.3389/fimmu.2022.855701